Last updated: March 2026
ACP-105 is a partial androgen receptor agonist developed by Acadia Pharmaceuticals. Milder than LGD-4033 or RAD-140, it occupies the low-potency end of the SARM spectrum. Research interest includes muscle preservation, bone density, and emerging neuroprotective applications. All data from preclinical animal models.
ACP-105 is a selective androgen receptor modulator that binds AR with high affinity but acts as a partial agonist — it initiates receptor signaling but does not maximally activate the receptor. This partial activation profile is theorized to deliver anabolic effects with reduced androgenic and suppressive activity versus full agonists.
ACP-105 binds the androgen receptor with high selectivity but functions as a partial agonist. Unlike full agonists (testosterone, LGD-4033), it activates only a fraction of the receptor's signaling cascade. This results in lower anabolic potency but also reduced androgenic stimulation in non-target tissues like the prostate.
In rodent studies, ACP-105 demonstrated muscle weight preservation in castrated male models and supported bone mineral density at doses lower than testosterone. The anabolic-to-androgenic selectivity ratio appears favorable compared to testosterone in preclinical data, though less potent than full SARM agonists.
Androgen receptors are expressed throughout the CNS. Some animal studies have explored ACP-105 for cognitive and neuroprotective effects — particularly in aging and injury models. Acadia Pharmaceuticals' original interest partly included CNS applications. This represents very early-stage research with no human data.
Partial agonism theoretically reduces HPG axis suppression relative to full AR agonists like LGD-4033. ACP-105 may cause milder testosterone suppression at equivalent anabolic doses, though suppression still occurs and post-cycle considerations remain. Exact suppression magnitude in humans is uncharacterized.
⚠️ All data below is from animal studies (rodent models). ACP-105 lacks human clinical trial data. Figures represent preclinical findings only.
Testing and monitoring supplies for SARM research protocols.
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
This page is for educational purposes only. It is not medical advice. ACP-105 is not FDA approved and is not intended for human use. All data referenced is from preclinical animal studies. Do not use any research chemical without consulting a qualified medical professional.